WaveMan
WaveMan · Company
MAIA · Maia Biotechnology, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MAIA MAIA Biotechnology (MAIA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001878313
Quote by TradingView
Cluster · 4 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
22
13F, latest reported quarter

What the filings say about MAIA

Insiders, 180 days
+$556.6K net bought
4 buyers

MAIA Biotechnology insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, MAIA Biotechnology, Inc. insiders bought a net $556.6K of stock across 141 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Vitoc Vlad
Chief Executive Officer
BUY
2026-09-15 SECtraded 2026-09-14
73,000
$100.0K
-17.9%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 buys), the last on Jun 1, 2026.
  • -38.8% median (-5.0% mean) 90-day return after 26 previous buys.
  • The trade is 7.0% of the 1,049,121 shares held after it.
  • 1 other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Vitoc Vlad bought about $100.0K of MAIA on Sep 14, 2026; 1 other insider bought within 30 days and 22 funds added in the latest 13F quarter.
Guerrero Ramiro
Director
BUY
2026-09-14 SECtraded 2026-09-10
37,595
$49.5K
-14.2%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 buys), the last on Aug 28, 2026.
  • -29.2% median (-17.3% mean) 90-day return after 20 previous buys.
  • The trade is 4.9% of the 773,296 shares held after it.
  • 1 other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Guerrero Ramiro bought about $49.5K of MAIA on Sep 10, 2026; 1 other insider bought within 30 days and 22 funds added in the latest 13F quarter.
Guerrero Ramiro
Director
BUY
2026-09-01 SECtraded 2026-08-28
46,620
$62.9K
-16.1%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (24 buys), the last on Aug 27, 2026.
  • -29.2% median (-17.3% mean) 90-day return after 20 previous buys.
  • The trade is 6.3% of the 735,701 shares held after it.
  • 1 other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Guerrero Ramiro bought about $62.9K of MAIA on Aug 28, 2026; 1 other insider bought within 30 days and 22 funds added in the latest 13F quarter.
Guerrero Ramiro
Director
BUY
2026-09-01 SECtraded 2026-08-27
78,239
$108.8K
-16.1%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 buys), the last on Aug 26, 2026.
  • -29.2% median (-17.3% mean) 90-day return after 20 previous buys.
  • The trade is 11.4% of the 689,081 shares held after it.
  • 1 other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Guerrero Ramiro bought about $108.8K of MAIA on Aug 27, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days and 22 funds added in the latest 13F quarter.
Guerrero Ramiro
Director
BUY
2026-09-01 SECtraded 2026-08-26
8,931
$12.4K
-16.1%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 buys), the last on Aug 24, 2026.
  • -29.2% median (-17.3% mean) 90-day return after 20 previous buys.
  • The trade is 1.5% of the 610,842 shares held after it.
  • 1 other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Guerrero Ramiro bought about $12.4K of MAIA on Aug 26, 2026; 1 other insider bought within 30 days and 22 funds added in the latest 13F quarter.
141 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 136 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$556.6K over 180 days
+$352.3K over 90 days · +$201.1K of it by a 10%+ holder
more than 86% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
22 funds bought in last quarter
below 67% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.9% of the float short (float per yahoo 2026-10-26) · 3.4 days to cover · settled 2026-09-30
below 52% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MAIA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-15.4%12M
-36%+15%+66%+117%2025-102025-122026-022026-042026-062026-082026-10 2026-08-27 · Guerrero Ramiro bought $108.8K2026-06-01 · Vitoc Vlad bought $101.1K2026-06-01 · Smith Stan bought $100.5K2026-09-14 · Vitoc Vlad bought $100.0K2025-12-22 · Louie Ngar Yee bought $99.7K2025-12-22 · Smith Stan bought $69.8K2026-08-28 · Guerrero Ramiro bought $62.9K2025-11-28 · Vitoc Vlad bought $57.0K2025-12-22 · CHAOUKI STEVEN M bought $49.8K2026-09-10 · Guerrero Ramiro bought $49.5K2025-11-26 · Vitoc Vlad bought $23.1K2025-11-26 · Luput Cristian bought $21.6K2025-11-28 · Luput Cristian bought $20.1K2026-08-20 · Guerrero Ramiro bought $16.3K2025-11-26 · Smith Stan bought $15.6K2025-11-25 · Smith Stan bought $14.7K2026-08-26 · Guerrero Ramiro bought $12.4K2025-11-25 · Vitoc Vlad bought $10.2K2025-11-24 · Smith Stan bought $9.9K2025-11-24 · Vitoc Vlad bought $9.9K2025-11-25 · Luput Cristian bought $9.8K2025-12-05 · Smith Stan bought $5.5K2025-12-05 · Smith Stan bought $5.5K2026-06-01 · Gryaznov Sergei bought $2.7K2026-08-24 · Guerrero Ramiro bought $2.4K2025-11-21 · Vitoc Vlad bought $1.7K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MAIA: institutional holders (13F)

13F holdings, latest reported quarter
Solas Capital Management, LLC
3,030,845 sh
$4.4M
Alyeska Investment Group, L.P.
2,500,000 sh
$3.6M
VANGUARD CAPITAL MANAGEMENT LLC
2,413,270 sh
$3.5M
683 Capital Management, LLC
1,066,666 sh
$1.5M
Centric Wealth Management
796,723 sh
$1.1M

Congress trades in MAIA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MAIA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MAIA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$109.4K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$257.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$17.3K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$962.1K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$244.4K position · as of 2026-05-31
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$57.2K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
1 active
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $556.6K bought by insiders over 180 days, 22 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MAIA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.00x
long-term debt only, 2022-06-30 (48 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-218.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-136.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-206.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$69.9M
market value at close 2026-10-23 on 2026-08-10 shares, plus long-term debt only, 2022-06-30 (48 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/a$0$0$0
Operating income-$24.3M-$17.0M-$20.2M-$16.2M
Net income-$22.4M-$23.3M-$19.8M-$15.8M
EPS (diluted)-0.70-1.05-1.49-1.75
Operating cash flow-$18.8M-$15.7M-$13.1M-$12.1M
Cash$0$0$0$0
SEC XBRL, fiscal years, as known on 2026-10-27

MAIA Stock Sonar score 5/7 axes

Find similar shapesCompare

MAIA ranks highest on financial health (99th percentile) and insider conviction (89th), and lowest on profitability (14th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
14
Inputs
  • Return on equity-218.7% · 15 pct, sector of 545
  • Return on assets-136.7% · 17 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-206.9% · 10 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Insider conviction
89
Inputs
  • Net Form 4 buying (codes P and S), 180d$557K · 85 pct, sector of 428
  • Insider buyers, 180d4 · 94 pct, sector of 437
Institutional and government
33
Inputs
  • Funds adding, latest quarter22 · 33 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+4.9% · 59 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+10.8% · 49 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MAIA filings, in plain words

Are MAIA Biotechnology insiders buying or selling MAIA?

In the 180 days to 2026-10-27, MAIA Biotechnology insiders were net buyers, a net $556.6K across purchases and sales reported on Form 4, by 4 buyers.

Read the full summary

In the 180 days to 2026-10-27, MAIA Biotechnology insiders were net buyers of MAIA, a net $556.6K across purchases and sales reported on Form 4 by 4 buyers. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies